281 related articles for article (PubMed ID: 32255766)
1. CX3CR1-CD8+ T cells are critical in antitumor efficacy but functionally suppressed in the tumor microenvironment.
Yamauchi T; Hoki T; Oba T; Saito H; Attwood K; Sabel MS; Chang AE; Odunsi K; Ito F
JCI Insight; 2020 Apr; 5(8):. PubMed ID: 32255766
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral Tcf1
Siddiqui I; Schaeuble K; Chennupati V; Fuertes Marraco SA; Calderon-Copete S; Pais Ferreira D; Carmona SJ; Scarpellino L; Gfeller D; Pradervand S; Luther SA; Speiser DE; Held W
Immunity; 2019 Jan; 50(1):195-211.e10. PubMed ID: 30635237
[TBL] [Abstract][Full Text] [Related]
3. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1
Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC
Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236
[TBL] [Abstract][Full Text] [Related]
4. CD8-mediated type 1 antitumor responses selectively modulate endogenous differentiated and nondifferentiated T cell localization, activation, and function in progressive breast cancer.
Dobrzanski MJ; Reome JB; Hylind JC; Rewers-Felkins KA
J Immunol; 2006 Dec; 177(11):8191-201. PubMed ID: 17114496
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral CD8
Horton BL; Williams JB; Cabanov A; Spranger S; Gajewski TF
Cancer Immunol Res; 2018 Jan; 6(1):14-24. PubMed ID: 29097422
[TBL] [Abstract][Full Text] [Related]
6. CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy.
Yan Y; Cao S; Liu X; Harrington SM; Bindeman WE; Adjei AA; Jang JS; Jen J; Li Y; Chanana P; Mansfield AS; Park SS; Markovic SN; Dronca RS; Dong H
JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669928
[TBL] [Abstract][Full Text] [Related]
7. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.
Moran AE; Polesso F; Weinberg AD
J Immunol; 2016 Sep; 197(6):2509-21. PubMed ID: 27503208
[TBL] [Abstract][Full Text] [Related]
9. The helminth-derived peptide GK-1 induces an anti-tumoral CD8 T cell response associated with downregulation of the PD-1/PD-L1 pathway.
Rodríguez-Rodríguez N; Madera-Salcedo IK; Bugarin-Estrada E; Sánchez-Miranda E; Torres-García D; Cervantes-Torres J; Fragoso G; Rosetti F; Crispín JC; Sciutto E
Clin Immunol; 2020 Mar; 212():108240. PubMed ID: 31299381
[TBL] [Abstract][Full Text] [Related]
10. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
11. Expansion of Tumor-Infiltrating CD8
Fernandez-Poma SM; Salas-Benito D; Lozano T; Casares N; Riezu-Boj JI; Mancheño U; Elizalde E; Alignani D; Zubeldia N; Otano I; Conde E; Sarobe P; Lasarte JJ; Hervas-Stubbs S
Cancer Res; 2017 Jul; 77(13):3672-3684. PubMed ID: 28522749
[TBL] [Abstract][Full Text] [Related]
12. Predictive and Prognostic Implications of Circulating CX3CR1
Abdelfatah E; Long MD; Kajihara R; Oba T; Yamauchi T; Chen H; Sarkar J; Attwood K; Matsuzaki J; Segal BH; Dy GK; Ito F
Cancer Res Commun; 2023 Mar; 3(3):510-520. PubMed ID: 37009132
[TBL] [Abstract][Full Text] [Related]
13. Mouse PVRIG Has CD8
Murter B; Pan X; Ophir E; Alteber Z; Azulay M; Sen R; Levy O; Dassa L; Vaknin I; Fridman-Kfir T; Salomon R; Ravet A; Tam A; Levin D; Vaknin Y; Tatirovsky E; Machlenkin A; Pardoll D; Ganguly S
Cancer Immunol Res; 2019 Feb; 7(2):244-256. PubMed ID: 30659055
[TBL] [Abstract][Full Text] [Related]
14. Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome.
Araujo B de Lima V; Borch A; Hansen M; Draghi A; Spanggaard I; Rohrberg K; Reker Hadrup S; Lassen U; Svane IM
Cytotherapy; 2020 Apr; 22(4):204-213. PubMed ID: 32201034
[TBL] [Abstract][Full Text] [Related]
15. Immune-Checkpoint Blockade Opposes CD8
Pfannenstiel LW; Diaz-Montero CM; Tian YF; Scharpf J; Ko JS; Gastman BR
Cancer Immunol Res; 2019 Mar; 7(3):510-525. PubMed ID: 30728151
[TBL] [Abstract][Full Text] [Related]
16. Adoptive cell therapy using PD-1
Jing W; Gershan JA; Blitzer GC; Palen K; Weber J; McOlash L; Riese M; Johnson BD
J Immunother Cancer; 2017; 5():51. PubMed ID: 28642819
[TBL] [Abstract][Full Text] [Related]
17. T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma.
Tähtinen S; Blattner C; Vähä-Koskela M; Saha D; Siurala M; Parviainen S; Utikal J; Kanerva A; Umansky V; Hemminki A
J Immunother; 2016; 39(9):343-354. PubMed ID: 27741089
[TBL] [Abstract][Full Text] [Related]
18. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.
Gattinoni L; Klebanoff CA; Palmer DC; Wrzesinski C; Kerstann K; Yu Z; Finkelstein SE; Theoret MR; Rosenberg SA; Restifo NP
J Clin Invest; 2005 Jun; 115(6):1616-26. PubMed ID: 15931392
[TBL] [Abstract][Full Text] [Related]
19. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
[TBL] [Abstract][Full Text] [Related]
20. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
